Major Events - Silyus (09927) starts its public offering with cornerstone subscriptions amounting to $826.5 million, with 70% of the funds allocated for R&D [1] - Dipo Technology (01384) sees a public offering in Hong Kong oversubscribed by 7569.83 times, raising approximately HK$609.8 million from the global offering [1] - Bama Tea (06980) experiences a public offering in Hong Kong oversubscribed by 2680.04 times, with a share price set at HK$50 [1] - Cambridge Technology (06166) has its public offering in Hong Kong oversubscribed by 338.7 times, with a share price of HK$68.88 [1] - Sany Heavy Industry (06031) reports a public offering in Hong Kong oversubscribed by 52.93 times, netting approximately HK$13.307 billion from the global offering [1] - Kangzhe Pharmaceutical (00867) signs a distribution agreement with Novartis for ophthalmic drugs [1] - Postal Savings Bank of China (01658) is approved to establish a financial asset investment company [1] - Meidong Automotive (01268) invests $20 million to subscribe for shares in Silyus [1] - China Aluminum (02600) plans to increase capital in Yunnan Aluminum Foil by a total of 906.45 million yuan through cash or asset contributions from subsidiaries [1] - China Coal Energy (01898) subsidiary intends to acquire the remaining 30% stake in a new energy company for 115 million yuan [1] - China Software International (00354) successfully signs a project for the Wuhan Cybersecurity Base Intelligent Computing Center, promoting AI industry development in Wuhan [1] - China Gold International (02099) is included in the Hang Seng Hong Kong Chinese Enterprises Index [1] - Beike-W (02423) has its MSCI ESG rating upgraded to "AA" [1] Operating Performance - China National Pharmaceutical Group (01099) reports a net profit of approximately 5.307 billion yuan for the first three quarters, a year-on-year increase of 0.53% [2] - Qingdao Beer Co. (00168) announces a net profit of 5.274 billion yuan for the first three quarters, up 5.7% year-on-year [2] - Yuehai Investment (00270) reports a net profit of 4.067 billion HKD for the first three quarters, a 13.2% increase year-on-year [2] - China Southern Airlines (01055) posts a net profit of 2.307 billion yuan for the first three quarters, a year-on-year growth of 17.4% [2] - Zhongchuang Zhiling (00564) announces a net profit of 3.645 billion yuan for the first three quarters, up 19.17% year-on-year [2] - China Aluminum (02600) reports a net profit of 10.872 billion yuan for the first three quarters, a 20.65% increase year-on-year [2] - Heng Rui Pharmaceutical (01276) announces a net profit of 5.751 billion yuan for the first three quarters, a year-on-year increase of 24.5% [2] - Jihong Co. (02603) reports a net profit of 216 million yuan for the first three quarters, a significant increase of 60.11% year-on-year [2] - China Foreign Transport (00598) announces a net profit of 2.679 billion yuan for the first three quarters, down 5.17% year-on-year [2] - China Coal Energy (01898) reports a net profit of 12.485 billion yuan for the first three quarters, a decline of 14.6% year-on-year [2] - Fuyao Glass (06865) announces a net profit of 638 million yuan for the first three quarters, down 50.79% year-on-year [2] - Fenmei Packaging (00468) reports a profit attributable to equity holders of 76.982 million yuan for the first nine months, a decrease of 59.13% year-on-year [2] - CanSino Biologics (06185) announces a net profit of 14.44 million yuan for the first three quarters [2] - Wuzhou Real Estate (00230) reports a contract sales amount of approximately 3.22 billion yuan for the first nine months, a year-on-year decline of about 24.2% [2] Retail Performance - Anta Sports (02020) reports a low single-digit positive growth in retail sales for its Anta brand products in the third quarter [3]

Group 1 - The company, Kangzheng Pharmaceutical, has signed a distribution agreement with Novartis Pharma Services AG for the exclusive import, distribution, sales, and promotion rights of two injectable products in mainland China [1][2] - The agreement covers the products Lezhu Single Antibody Injection (brand name: Noshide) and Busizhu Single Antibody Injection (brand name: Beiyoushi), with Novartis responsible for production and supply [1] - The collaboration is set to last for five years from the effective date of the agreement [1] Group 2 - This partnership is expected to enhance the competitiveness of Kangzheng Weisheng in the ophthalmology sector, which already covers diseases such as retinal diseases, visual fatigue, and glaucoma [2] - The addition of Noshide and Beiyoushi will synergize with existing products, including the exclusive eye drop medication and glaucoma treatment device, improving academic brand competitiveness in the ophthalmology field [2] - The professional ophthalmology team at Kangzheng Weisheng will integrate market channels and academic resources, leading to improved overall team efficiency and a positive impact on the company's performance [2]

Group 1 - The company, Kangzheng Pharmaceutical, has signed a distribution agreement with Novartis Pharma Services AG for the exclusive import, distribution, sales, and promotion rights of two ophthalmic products in mainland China [1][2] - The agreement covers the products Ranibizumab Injection (trade name: 诺适得®) and Brolucizumab Injection (trade name: 倍优适®) for a duration of five years [1] - Novartis will continue to be responsible for the production and supply of these products [1] Group 2 - This collaboration is expected to enhance the competitiveness of Kangzheng Weisheng, the company's ophthalmology division, in the field of eye diseases [2] - The addition of these products will synergize with existing offerings, including the exclusive drug and medical device currently available, thereby strengthening the academic brand competitiveness in ophthalmology [2] - The professional ophthalmology team at Kangzheng Weisheng will integrate market channels and academic resources, which is anticipated to have a positive impact on the company's overall performance [2]